Cargando…

HER2 Status in High-Risk Endometrial Cancers (PORTEC-3): Relationship with Histotype, Molecular Classification, and Clinical Outcomes

SIMPLE SUMMARY: HER2 testing in endometrial cancer (EC) has gained renewed interest as a therapeutic target. However, HER2 status has not been investigated in the context of the molecular EC classification. Here, we aimed to determine the clinicopathological features and prognostic significance of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vermij, Lisa, Horeweg, Nanda, Leon-Castillo, Alicia, Rutten, Tessa A., Mileshkin, Linda R., Mackay, Helen J., Leary, Alexandra, Powell, Melanie E., Singh, Naveena, Crosbie, Emma J., Smit, Vincent T.H.B.M., Creutzberg, Carien L., Bosse, Tjalling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7795222/ https://www.ncbi.nlm.nih.gov/pubmed/33375706 http://dx.doi.org/10.3390/cancers13010044

Ejemplares similares

p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial
por: Vermij, Lisa, et al.
Publicado: (2022)

Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer
por: Horeweg, Nanda, et al.
Publicado: (2023)

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy
por: León-Castillo, Alicia, et al.
Publicado: (2020)

Performance of a HER2 testing algorithm specific for p53‐abnormal endometrial cancer
por: Vermij, Lisa, et al.
Publicado: (2021)

Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry
por: Vermij, Lisa, et al.
Publicado: (2023)

Tertiary lymphoid structures critical for prognosis in endometrial cancer patients
por: Horeweg, Nanda, et al.
Publicado: (2022)

Prevalence and Prognosis of Lynch Syndrome and Sporadic Mismatch Repair Deficiency in Endometrial Cancer
por: Post, Cathalijne C B, et al.
Publicado: (2021)

Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy
por: van den Heerik, Anne Sophie V M, et al.
Publicado: (2021)

Patients' and clinicians' preferences for adjuvant chemotherapy in endometrial cancer: an ANZGOG substudy of the PORTEC-3 intergroup randomised trial
por: Blinman, Prunella, et al.
Publicado: (2016)

Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer
por: de Boer, S M, et al.
Publicado: (2018)

Incorporation of molecular characteristics into endometrial cancer management
por: Vermij, Lisa, et al.
Publicado: (2019)

Limited impact of intratumour heterogeneity on molecular risk assignment in endometrial cancer
por: van Esterik, Manouk, et al.
Publicado: (2017)

PORTEC-4a: international randomized trial of molecular profile-based adjuvant treatment for women with high-intermediate risk endometrial cancer
por: van den Heerik, Anne Sophie V M, et al.
Publicado: (2020)

Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors
por: Wortman, Bastiaan G., et al.
Publicado: (2019)

The evolving role of morphology in endometrial cancer diagnostics: From histopathology and molecular testing towards integrative data analysis by deep learning
por: Fremond, Sarah, et al.
Publicado: (2022)

QPOLE: A Quick, Simple, and Cheap Alternative for POLE Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain Reaction
por: Van den Heerik, Anne Sophie V.M., et al.
Publicado: (2023)

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial
por: de Boer, Stephanie M, et al.
Publicado: (2018)

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial
por: de Boer, Stephanie M, et al.
Publicado: (2019)

Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition
por: Eggink, Florine A., et al.
Publicado: (2016)

Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy
por: Wortman, B. G., et al.
Publicado: (2018)

Clinical Behavior and Molecular Landscape of Stage I p53-Abnormal Low-Grade Endometrioid Endometrial Carcinomas
por: Jamieson, Amy, et al.
Publicado: (2023)

Prediction model for regional or distant recurrence in endometrial cancer based on classical pathological and immunological parameters
por: Versluis, M A, et al.
Publicado: (2015)

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: Diagnosis, Treatment and Follow-up
por: Colombo, Nicoletta, et al.
Publicado: (2016)

The Role of Radiotherapy in Endometrial Cancer: Current Evidence and Trends
por: Creutzberg, Carien L., et al.
Publicado: (2011)

Microsatellite instability derived JAK1 frameshift mutations are associated with tumor immune evasion in endometrioid endometrial cancer
por: Stelloo, Ellen, et al.
Publicado: (2016)

Prognostic Significance of POLE Proofreading Mutations in Endometrial Cancer
por: Church, David N., et al.
Publicado: (2014)

A Comparison of Death Domain-Associated Protein 6 in Different Endometrial Carcinomas Histotypes
por: Jin, Cao, et al.
Publicado: (2019)

Reproducibility of lymphovascular space invasion (LVSI) assessment in endometrial cancer
por: Peters, Elke E M, et al.
Publicado: (2019)

Statement of the Uterus Committee of the Gynaecological Oncology Working Group (AGO) on the PORTEC-3 study
por: Emons, Günther, et al.
Publicado: (2018)

Gene expression-based dissection of inter-histotypes, intra-histotype and intra-tumor heterogeneity in pediatric tumors
por: Ciceri, Sara, et al.
Publicado: (2022)

Ki-67 in endometrial cancer: scoring optimization and prognostic relevance for window studies
por: Kitson, Sarah, et al.
Publicado: (2017)

Ovarian carcinoma histotype in Lynch syndrome
por: Gilks, C. Blake, et al.
Publicado: (2017)

FIGO staging of endometrial cancer: 2023
por: Berek, Jonathan S., et al.
Publicado: (2023)

The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer
por: Jamieson, Amy, et al.
Publicado: (2021)

POLE proofreading mutation, immune response and prognosis in endometrial cancer
por: van Gool, Inge C., et al.
Publicado: (2015)

Clinicopathological and molecular characterisation of ‘multiple‐classifier’ endometrial carcinomas
por: León‐Castillo, Alicia, et al.
Publicado: (2020)

Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer
por: Ramchander, Neal C., et al.
Publicado: (2020)

Gastric (gastrointestinal)-type endometrial adenocarcinoma presenting as a solitary endometrial polyp: a case report and literature review on a novel and potentially aggressive endometrial cancer histotype
por: Bragantini, Emma, et al.
Publicado: (2023)

Histotype-specific copy-number alterations in ovarian cancer
por: Huang, Ruby YunJu, et al.
Publicado: (2012)

The Impact of Thymoma Histotype on Prognosis in a Worldwide Database
por: Weis, Cleo-Aron, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_o5odnaid6cvoitfholhnmv4686